Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Aaron Richterman, MD Profile picture
@AaronRichterman
Sep 2, 2020 • 5 tweets • 2 min read • Read on X
Really nice to see this WHO analysis in JAMA (along w 3 RCTs) put to bed the importance of corticosteroids in ventilated patients w COVID-19. A lot of good stuff here.

So what to do w steroids in those requiring supp O2 only? /1

jamanetwork.com/journals/jama/…
RECOVERY results suggest a mortality benefit in this population (supp O2 only), and I have seen basically every patient in this category receive dex, appropriately... but there are enough odd features of this single open-label trial that make me wonder. /2
Much of this nuance is explained well in this thread by @FranciscoMarty_



The main thing that nags me personally is how ridiculously high the mortality was in RECOVERY - 26.2% among those requiring O2 and receiving usual care /3 Image
This is much higher than what I've seen reported in other high-resource settings. Eg study from Boston 👇 found 15% mortality among ALL admitted patients (42% critically ill) /4

thelancet.com/journals/eclin…
Maybe @EricMeyerowitz can explain to me why mortality for people on supp O2 was so different in RECOVERY, but this, along with the even more dubious effect of dex in those not on O2, makes me question reflexively giving steroids to pts admitted with COVID-19 on low-flow O2 /end

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Aaron Richterman, MD

Aaron Richterman, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AaronRichterman

Aaron Richterman, MD Profile picture
May 31, 2023
Over 100 governments in low- and middle-income countries have introduced anti-poverty cash transfer programs over the last 3 decades

In new research, we examined the effects of these initiatives on the ultimate health outcome — mortality

Published today in @Nature /1 Image
We used >80 national surveys in 37 low- and middle-income countries to create longitudinal survival datasets for 4 million adults & 3 million children 2000-2019

About 1/2 the countries started cash transfer programs, & 1/2 the programs were unconditional (no strings attached) /2 Image
We used difference-in-difference models to show these programs led to a 20% reduction in mortality for women, and an 8% reduction in risk of death for children under 5
/3 Image
Read 8 tweets
Aaron Richterman, MD Profile picture
Nov 16, 2021
New pre-print from @EricMeyerowitz and me reviewing loads of new Delta transmission data.

One area we cover — updates on vaccines' effects on transmission in the Delta era 🧵 1/24

papers.ssrn.com/sol3/papers.cf…
First, to review, vaccines can provide:
-direct protection (reduction in infx/disease among vaccinated ppl)
-indirect protection (reduction in infection among all community members through ⬇️ transmission)
/2
nature.com/articles/s4157…
Indirect protection can be generated by
1) ⬇️ risk of infection (if person not infected, cannot transmit)
2) ⬇️ infectiousness of vaccinated person w infection

Prior to delta, 1) + 2) = substantial transmission reduction of 75%+. Our pre-delta review:
/3
academic.oup.com/ofid/advance-a…
Read 24 tweets
Aaron Richterman, MD Profile picture
Aug 24, 2021
As @mugecevik points out, despite the recent proliferation of vaccine studies using routinely collected testing data, the majority of these cannot be reliably be used to estimate VE vs all infections because they do not use systematic testing and/or control for confounding.
Vaccine protection against all infections is one important way (of several) that vaccines reduce transmission (discussed👇). Here is an updated table of high-quality studies assessing VE against infection, including just 3 from the delta era at the bottom
academic.oup.com/ofid/advance-a…
When using regular (or cross-sectional) systematic testing to estimate VE, you are really measuring VE against a composite of infection and duration of PCR-positivity, as highlighted recently by @dylanhmorris.
Fascinating discussion of these methods here sciencedirect.com/science/articl…
Read 4 tweets
Aaron Richterman, MD Profile picture
Aug 11, 2021
This 👇claim arises principally from Israeli data (which is unpublished in any form so will withhold judgment) and from the UK REACT 1 study, rounds 12 & 13. But... is the REACT 1 data likely to be solely explained by delta? 🧵
(study link spiral.imperial.ac.uk/handle/10044/1…)
This is the table in question. You can see VE of a combination of AZ/MRNA vs symptomatic infection was 83% (19-97%) in round 12, but only 59% (23-78%) in round 13. The concern of course is that this drop in VE is due to delta, which had completely taken over by round 13 /2
However, while 100% of the isolates identified in round 13 were delta, 80% in round 12 were also delta (20% were alpha). Any effect of delta on VE should have been partially seen in round 12. /3
Read 7 tweets
Aaron Richterman, MD Profile picture
Jul 31, 2021
The question at hand: what is the relative transmission potential of a vaccinated person who becomes infected with delta? This 👇new report from Singapore is much more informative on this question than the CT data released so far from Ptown and Wisconsin.
medrxiv.org/content/10.110…
First, importantly, reducing transmission potential of a person who becomes infected is only one component on the transmission reduction effect of the vaccines. The other: reducing the likelihood of becoming infected in the first place. We discuss here👇
academic.oup.com/ofid/advance-a…
We still await definitive evidence from systematic sampling on the ? of overall infection risk reduction with vaccination, but w strong protection vs symptomatic disease, expect that there will still be substantial protection (50+%) vs overall infection
nejm.org/doi/full/10.10…
Read 10 tweets
Aaron Richterman, MD Profile picture
Jan 12, 2021
Interesting poll. Selection/response bias aside, majority picked a low probability, but 40% still thought there was 10+% prob that vaccines will not substantially prevent transmission. This is why I have become convinced this concern is highly unlikely (borderline implausible) 🧵
1. Data from screening PCR at the time of the 2nd moderna mrna vaccine, showing reductions in asymptomatic PCR positivity. This is before the 2nd dose and if anything will underestimate effect. Will have additional confirmation from unblinding pcr and ab

2. Data from AZ vaccine chadox study is a mess, but they did weekly PCR screening and points in the same direction.
thelancet.com/action/showPdf… Image
Read 27 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(